Pfizer Reports Positive Survival Outcomes for Elrexfio in Multiple Myeloma

Pfizer has recently unveiled encouraging phase 2 outcomes for its monotherapy, Elrexfio (elranatamab-bcmm), in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM). These findings are part of the ongoing MagnetisMM clinical development programme and were presented at the European Hematology Association (EHA) Hybrid Congress.

Multiple myeloma (MM) is a highly aggressive and incurable blood cancer affecting plasma cells in the bone marrow. Globally, more than 187,000 new cases are diagnosed each year. The MagnetisMM programme aims to explore the efficacy of Elrexfio in treating MM, including RRMM and newly diagnosed MM, as a monotherapy and in combination with other therapies, both standard and novel.

The phase 2 open-label, multicenter study has been particularly focused on subcutaneous Elrexfio monotherapy. This involves administering two step-up priming doses followed by a weekly 76mg injection in patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-cluster of differentiation 38 antibody.

Elrexfio is a bispecific antibody that is delivered subcutaneously. It targets the B-cell maturation antigen, which is highly expressed on the surface of multiple myeloma cells, and CD3 receptors on the surface of T-cells. This dual binding activates T-cells to kill myeloma cells.

The study results are promising: Elrexfio achieved a median overall survival of 24.6 months and a median progression-free survival of 17.2 months in RRMM patients. Additionally, the safety and tolerability of the treatment were consistent with earlier studies.

Roger Dansey, Pfizer's chief development officer for oncology, noted that the latest results from MagnetisMM-3 underscore the promising efficacy of Elrexfio in a relapsed or refractory setting. This includes deep and durable responses, as well as the longest reported median progression-free survival among B-cell maturation antigen bispecific antibodies.

Based on the results from the MagnetisMM-3 trial, Elrexfio received approval from the European Commission in December 2023 for the treatment of adults with RRMM who have undergone at least three prior lines of therapy. This follows an earlier accelerated approval from the US Food and Drug Administration in August 2023 for adult RRMM patients who have received at least four prior lines of therapy.

In summary, Pfizer's Elrexfio has shown significant potential in treating heavily pre-treated relapsed or refractory multiple myeloma, offering new hope for patients facing this challenging cancer.